Short answer
Lantheus Holdings, Inc. (LNTH) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Lantheus signed a merger agreement with Curium US Holdings, signaling a pending change in ownership.
Lantheus Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Lantheus signed a merger agreement with Curium US Holdings, signaling a pending change in ownership
- Curium US Holdings will acquire Lantheus through wholly owned Coco Merger Sub
- Transaction terms and shareholder consideration require review of the separate merger-agreement 8-K
- Investor presentation provides management’s strategic rationale and transaction overview
Item 8.01 · Other Events
- CEO search paused, signaling merger-related uncertainty around standalone leadership planning
- Proposed acquisition remains subject to stockholder approval, regulatory clearances and other closing conditions
- Proxy statement will detail transaction terms, participant interests and stockholder voting considerations
- Merger could disrupt operations, divert management attention and affect employee, supplier and partner relationships
- CVR payments remain contingent on achieving specified milestones after closing
Item EX-99.1 · Exhibit EX-99.1
- Curium acquisition implies $102.50 cash per share at closing, plus non-transferable CVRs worth up to $12.00 per share
- Total consideration up to $114.50 per share and approximately $8.0 billion, including premiums of 38% to 60-day VWAP and 29% to 30-day VWAP
- CVR payouts depend on prostate diagnostics, neurology diagnostics and DEFINITY sales milestones through 2030
- Closing expected first half 2027, subject to shareholder and regulatory approvals; financing combines debt and equity
- Lantheus suspended FY 2026 guidance and will cease trading publicly after completion
Item EX-99.2 · Exhibit EX-99.2
- Definitive merger with Curium: $102.50 per share cash at closing, plus non-transferable CVRs worth up to $12.00 per share
- Total consideration up to $114.50 per share, representing up to approximately $8 billion transaction value
- Premiums: 38% to unaffected 60-day VWAP, 29% to 30-day VWAP, and 21% to May 21, 2026 closing price
- CVRs tied to prostate diagnostics, neurology diagnostics, and DEFINITY sales milestones through fiscal 2030
- Closing expected in 1H 2027, subject to Lantheus shareholder approval and required regulatory clearances
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lantheus Holdings, Inc. 8-K filings
Get the next LNTH 8-K as it lands
Follow LNTH for push alerts, or ask the research agent what this filing means.